Reuters logo
a month ago
BRIEF-RedHill Biopharma confirms initiation of late-stage study on its stomach infection drug
June 15, 2017 / 12:31 PM / a month ago

BRIEF-RedHill Biopharma confirms initiation of late-stage study on its stomach infection drug

1 Min Read

June 15 (Reuters) - RedHill Biopharma Ltd-

* RedHill biopharma announces confirmatory phase III study initiated with rhb-105 (talicia™) for H. Pylori infection

* RedHill Biopharma Ltd - confirmatory phase III study (eradicate hp 2) is expected to complete package required for a potential U.S. Nda for rhb-105 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below